RxDoctor Payments Data

Nanette Ortiz, MD

General Practice · Caguas, PRNPI 1487637476

Payments from drug & device makers

$1,811in general payments, 2019–2025

Across 70 payments — averaging $25.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$344
  • Johnson & Johnson$315
  • Lilly USA, LLC$276
  • GSK$221
  • Exact Sciences$203
  • Amarin Pharma, Inc.$90
  • plus $362 from 9 others

What the payments were for

  • Food & beverage$1,811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,811 in reported general payments places this provider in the 90th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,265
Medicare patients
22
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$240,277
TivicayDolutegravir Sodium36$80,579
EliquisApixaban53$78,780
MounjaroTirzepatide56$70,862
JardianceEmpagliflozin46$70,263
FarxigaDapagliflozin Propanediol37$47,783
JanuviaSitagliptin Phosphate39$47,061
JanumetSitagliptin Phos/Metformin Hcl32$47,028
TrulicityDulaglutide15$32,811
DescovyEmtricitabine/Tenofov Alafenam13$29,467
PrezcobixDarunavir/Cobicistat11$26,697
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$22,065
EntrestoSacubitril/Valsartan15$20,324
PifeltroDoravirine12$20,235
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$17,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$344$240,277127 claims
Lilly USA, LLCMounjaro, Trulicity$276$103,67271 claims
PfizerEliquis$40$78,78053 claims
Boehringer IngelheimJardiance$49$70,26346 claims
Johnson & JohnsonPrezcobix, Xarelto$315$36,55223 claims
GSKTrelegy Ellipta$221$22,06523 claims
NovartisEntresto$52$20,32415 claims
Sanofi-aventis U.S. LLCLantus$15$3,07517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →